音乐支持的语音康复在帕金森病中的应用：对嗓音强度和言语表现的影响

文献信息

中文摘要

运动减退性构音障碍是帕金森病（PD）中一种高度普遍且导致功能残疾的沟通障碍，包括发声过弱、构音不精确和言语加速。音乐支持的语音康复——通过Accent Method（AM）实施，这是一种基于节奏和呼吸的语音治疗方法，建立在呼吸-发声-韵律协调的层级基础上——通过利用外部节律性听觉提示对PD运动控制的促进效应，为治疗PD构音障碍提供了有理论依据的机制。尽管AM在斯堪的纳维亚中心广泛临床使用，但其对PD嗓音强度和言语表现影响的严格对照证据仍然有限。前瞻性、平行组、随机对照试验，比较结构化的四阶段PD适应性AM方案与主动非特异性对照方案（嗓音卫生和一般呼吸练习），持续20周。92名特发性PD成人（Hoehn和Yahr分期2-3）被随机分配到音乐支持的AM康复组（n=46）或主动对照组（n=46）。盲法评估者在基线和第6、12、20周评估结果。主要结果：嗓音障碍指数-30（VHI-30）。次要结果：GRBAS感知性发声困难量表、声压级（SPL）、最大发声时间（MPT）、声学参数（基频微扰、振幅微扰、基频[F0]）、由盲法朴素听者评定的言语清晰度、UPDRS言语子项和PDQ-39沟通子量表。第20周时所有组间比较均支持音乐支持的AM康复（所有P<0.001，Bonferroni校正；调整α=0.005）。VHI-30改善：AM组-36.8分 vs. 对照组-9.4分；组间差异26.8分（95%CI：22.2-31.4；Cohen's d=2.47）。嗓音强度（SPL）在AM组提高+14.8 dB，而对照组提高+4.3 dB——改善幅度几乎是对照组的三倍。言语清晰度在AM组从67.4%提高到84.6%，而对照组从68.1%提高到73.4%（组间差异+17.2个百分点），代表从临床受损的清晰度向接近功能性沟通水平的转变。基频微扰从4.12±0.98%降至1.04±0.31%（AM组），而对照组从4.08±0.94%降至2.96±0.77%；振幅微扰从10.41±2.37%降至3.18±0.84%，而对照组从10.28±2.29%降至6.74±1.61%。所有领域的效应量为大至极大（Cohen's d范围：1.41-2.47）。使用PD适应性Accent Method的音乐支持语音康复，与主动非特异性对照方案相比，在嗓音强度、声学稳定性、言语清晰度和沟通相关生活质量方面产生了大而一致且具有临床意义的改善。这些发现确立了AM作为PD相关运动减退性构音障碍的循证行为管理选择。与LSVT LOUD和SPEAK OUT!进行头对头比较试验是必要的下一步。

英文摘要

Hypokinetic dysarthria is a highly prevalent and functionally disabling communication disorder in Parkinson's disease (PD), encompassing hypophonia, imprecise articulation, and festinating speech. Music-supported vocal rehabilitation-operationalized through the Accent Method (AM), a rhythm- and breathing-based voice therapy approach grounded in hierarchical respiratory-phonatory-prosodic coordination-offers a theoretically grounded mechanism for addressing PD dysarthria by exploiting the well-documented facilitatory effect of external rhythmic auditory cueing on motor control in PD. Despite widespread clinical use of the AM in Scandinavian centers, rigorous controlled evidence for its effects on voice intensity and speech performance in PD remains limited. Prospective, parallel-group, randomized controlled trial comparing a structured, four-phase PD-adapted AM protocol with an active nonspecific control program (vocal hygiene and general breathing exercises) over 20 weeks. Ninety-two adults with idiopathic PD (Hoehn and Yahr stages 2-3) were randomized to music-supported AM rehabilitation (n = 46) or active control (n = 46). Blinded assessors evaluated outcomes at baseline and at 6, 12, and 20 weeks. Primary outcome: Voice Handicap Index-30 (VHI-30). Secondary outcomes: GRBAS perceptual dysphonia scale, sound pressure level (SPL), maximum phonation time (MPT), acoustic parameters (jitter, shimmer, fundamental frequency [F0]), speech intelligibility rated by blinded naive listeners, UPDRS speech sub-item, and PDQ-39 communication subscale. All between-group comparisons at 20 weeks favored music-supported AM rehabilitation (all P < 0.001, Bonferroni corrected; adjusted α = 0.005). VHI-30 improvement: -36.8 points (AM) vs. -9.4 points (Control); between-group difference 26.8 points (95% CI: 22.2-31.4; Cohen's d = 2.47). Voice intensity (SPL) improved by +14.8 dB in the AM group versus +4.3 dB in the control group-a nearly threefold greater improvement. Speech intelligibility improved from 67.4% to 84.6% in the AM group versus 68.1% to 73.4% in the control group (+17.2%-point between-group difference), representing a movement from clinically impaired intelligibility to near-functional communicative levels. Jitter normalized from 4.12 ± 0.98% to 1.04 ± 0.31% (AM) versus 4.08 ± 0.94% to 2.96 ± 0.77% (Control), and shimmer from 10.41 ± 2.37% to 3.18 ± 0.84% versus 10.28 ± 2.29% to 6.74 ± 1.61%. Effect sizes were large to very large across all domains (Cohen's d range: 1.41-2.47). Music-supported vocal rehabilitation using the PD-adapted Accent Method yields large, consistent, and clinically meaningful improvements in voice intensity, acoustic stability, speech intelligibility, and communication-related quality of life compared with an active nonspecific control program. These findings establish the AM as an evidence-based behavioral management option for PD-associated hypokinetic dysarthria. Head-to-head comparative trials against LSVT LOUD and SPEAK OUT! are the essential next step.